RU2017128308A - Синтез ингибитора тирозинкиназы брутона - Google Patents

Синтез ингибитора тирозинкиназы брутона Download PDF

Info

Publication number
RU2017128308A
RU2017128308A RU2017128308A RU2017128308A RU2017128308A RU 2017128308 A RU2017128308 A RU 2017128308A RU 2017128308 A RU2017128308 A RU 2017128308A RU 2017128308 A RU2017128308 A RU 2017128308A RU 2017128308 A RU2017128308 A RU 2017128308A
Authority
RU
Russia
Prior art keywords
compound
formula
ibrutinib
phenoxyphenyl
pyrazolo
Prior art date
Application number
RU2017128308A
Other languages
English (en)
Russian (ru)
Other versions
RU2017128308A3 (enExample
Inventor
Сирил БЕНХАЙМ
Вей ЧЭНЬ
Эрик Голдман
Андрас ХОВАТ
Филип Пай
Марк С. СМИТ
Эрик Дж. ВЕРНЕР
Original Assignee
Фармасайкликс Элэлси
Янссен Фармасеутика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс Элэлси, Янссен Фармасеутика Нв filed Critical Фармасайкликс Элэлси
Publication of RU2017128308A publication Critical patent/RU2017128308A/ru
Publication of RU2017128308A3 publication Critical patent/RU2017128308A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2017128308A 2015-01-14 2016-01-14 Синтез ингибитора тирозинкиназы брутона RU2017128308A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
RU2017128308A true RU2017128308A (ru) 2019-02-14
RU2017128308A3 RU2017128308A3 (enExample) 2019-10-24

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017128308A RU2017128308A (ru) 2015-01-14 2016-01-14 Синтез ингибитора тирозинкиназы брутона

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN107108640A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712440C2 (ru) * 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба
RU2818458C2 (ru) * 2019-05-21 2024-05-02 Янссен Фармацевтика Нв Способы и промежуточные соединения для получения ингибитора btk

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
CN110944999A (zh) 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
KR20220011669A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
JP7658916B2 (ja) * 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
EP2228369A1 (en) * 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712440C2 (ru) * 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба
RU2818458C2 (ru) * 2019-05-21 2024-05-02 Янссен Фармацевтика Нв Способы и промежуточные соединения для получения ингибитора btk

Also Published As

Publication number Publication date
SG10201906517VA (en) 2019-08-27
CA2971460A1 (en) 2016-07-21
WO2016115356A1 (en) 2016-07-21
AU2016206693A1 (en) 2017-07-13
CN113816962A (zh) 2021-12-21
KR20170102887A (ko) 2017-09-12
MX2017009154A (es) 2017-10-12
BR112017015206A2 (pt) 2018-06-19
IL308276A (en) 2024-01-01
HK1246293A1 (zh) 2018-09-07
US20220098200A1 (en) 2022-03-31
CN107108640A (zh) 2017-08-29
US20180009814A1 (en) 2018-01-11
SG11201705678YA (en) 2017-08-30
CA3210320A1 (en) 2016-07-21
JP2021035947A (ja) 2021-03-04
CA2971460C (en) 2023-10-10
MA41350A (fr) 2017-11-21
EP3245208A4 (en) 2018-10-17
MX394327B (es) 2025-03-24
JP2018502077A (ja) 2018-01-25
BR112017015206B1 (pt) 2023-04-11
MX2019008815A (es) 2019-09-26
US20250197404A1 (en) 2025-06-19
ZA201704338B (en) 2023-10-25
US20200347064A1 (en) 2020-11-05
EP3245208A1 (en) 2017-11-22
US20190367518A1 (en) 2019-12-05
RU2017128308A3 (enExample) 2019-10-24
IL253020A0 (en) 2017-08-31
MX366827B (es) 2019-07-25
IL322449A (en) 2025-09-01
AU2020230323A1 (en) 2020-10-01
US20240158400A1 (en) 2024-05-16
IL274716A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
RU2015103694A (ru) Способы синтеза спиро-оксиндольных соединений
RU2013112946A (ru) Способ получения промежуточных соединений для получения ингибиторов nep
RU2014106757A (ru) Огнегасительная пена с содержанием силоксана
JP2018502077A5 (enExample)
EA201290872A1 (ru) Способ получения бензоксаборолов
RU2015136528A (ru) Сельскохозяйственный водный суспензионный химический состав
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
RU2013151867A (ru) Ингибиторы гидролазы амидов жирных кислот для лечения боли
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
CA2859003A1 (en) Optical resolution method for bicyclic compound using asymmetric catalyst
Nemoto et al. Synthesis of 6, 14-epoxymorphinan derivatives and their pharmacologies
FR2970254B1 (fr) Procede de preparation de carbonate d'alcool
AR066054A1 (es) Proceso para preparar galantamina
EP1235788B1 (en) Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties
RU2007125604A (ru) Производные гемина или их фармацевтически приемлемые соли, способ получения, композиция и применение
KR20150064749A (ko) 알콕시카르보닐 이소티오시아네이트의 제조 방법
AR074151A1 (es) Un derivado de benzoilbencenoacetamida, proceso de preparacion del mismo, forma polimorfica b de dicho compuesto, proceso de obtencion de dicha forma polimorfica b y su uso
CN105669475A (zh) 一种达泊西汀的制备方法及盐酸达泊西汀
RU2016113336A (ru) Производные оксимов 4-бензоилпиридина, обладающие противосудорожной активностью, как средства лечения эпилепсии и пароксизмальных состояний
RU2016146200A (ru) Способ производства эфира (мет)акриловой кислоты и способ производства ароматического эфира карбоновой кислоты
ES2657894T3 (es) Preparación de un derivado de ácido 1-amino-3-hidroxi-ciclobutano-1-carboxílico
CA3074247A1 (en) Process for the preparation of ixazomib citrate
AR089325A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
RU2007146394A (ru) Способы получения гетероциклических соединений

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220111